Search
Research
Ending tuberculosis: challenges and opportunitiesDespite impacting mankind since ancient times, tuberculosis (TB) persists as the leading cause of death from an infectious disease. TB can remain latent and further research is required to understand activation risk and the risks vs. the benefits of treating latent infection. Drug resistance poses an escalating threat to treating active disease and achieving cure.
Research
Prioritizing high-risk populations for soil-transmitted helminth control in the Western Pacific RegionTo achieve targets set within the 2030 Sustainable Development Agenda and the 2021–2030 Neglected Tropical Diseases (NTD) Roadmap, the World Health Organization identify the need for improved data analytics to inform NTD control programs.
Research
An Overview of the Skin Microbiome, the Potential for Pathogen Shift, and Dysbiosis in Common Skin PathologiesRecent interest in the diverse ecosystem of bacteria, fungi, parasites, and viruses that make up the skin microbiome has led to several studies investigating the microbiome in healthy skin and in a variety of dermatological conditions.
Research
Session Rating of Perceived Exertion Is a Valid Method to Monitor Intensity of Exercise in Adults with Acute Burn InjuriesMeasuring exercise intensity for safety and to inform prescription in acute burn survivors, is challenging. This study aimed to assess the validity of adult patient end-of-workout rating of session perceived exertion (sRPE); and calculated training load (TL) (sRPE × session duration) as measures of exercise intensity. Secondly, the study aimed to compare clinician and patient perception of exercise effort during physiotherapist-led sessions.
Research
Implementation Fidelity of a Smartphone Application for Population-Based General Movement Assessment: The Early Moves StudyTo describe the infant and maternal characteristics of the Early Moves cohort and to assess representativeness to the general population, and to evaluate the implementation fidelity of an application-based collection of General Movement Assessment (GMA) videos at writhing and fidgety age.
Research
An Assessment of Clinical Continuous Glucose Monitoring Targets for Older and High-Risk People Living with Type 1 DiabetesTo assess relationships between continuous glucose monitoring (CGM) time in range (TIR), 70-180 mg/dL, time below range (TBR), <70 mg/dL, time above range (TAR), >180 mg/dL, and glucose coefficient of variation (CV) in relation to currently recommended clinical CGM targets for older people, which recommend reduced TIR and TBR targets relative to the general type 1 diabetes population.
One hundred years after the discovery of insulin, technology advancements are being heralded as the dawn of a new era for managing type 1 diabetes (T1D) in young people.
News & Events
Improving the lives of kids with Type 1 DiabetesDiabetes research got a huge boost when the WA Children’s Diabetes Research and Education Centre for Research Excellence opened late last year.
Research
Vascular Effects of ACE (Angiotensin-Converting Enzyme) Inhibitors and Statins in Adolescents With Type 1 DiabetesAn increased albumin-creatinine ratio within the normal range can identify adolescents at higher risk of developing adverse cardio-renal outcomes as they progress into adulthood. Utilizing a parallel randomized controlled trial and observational cohort study, we characterized the progression of vascular phenotypes throughout this important period and investigated the effect of ACE (angiotensin-converting enzyme) inhibitors and statins in high-risk adolescents.
Research
Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled TrialTo investigate glycemic and psychosocial outcomes with hybrid closed-loop (HCL) versus user-determined insulin dosing with multiple daily injections (MDI) or insulin pump (i.e., standard therapy for most adults with type 1 diabetes). Adults with type 1 diabetes using MDI or insulin pump without continuous glucose monitoring (CGM) were randomized to 26 weeks of HCL (Medtronic 670G) or continuation of current therapy.